January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
6 citations
,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
July 2024 in “Reactions Weekly”
April 2025 in “Egyptian journal of Immunology” Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
July 2024 in “Journal of Investigative Dermatology”
August 2023 in “Clinical and experimental dermatology and therapies” Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.
3 citations
,
December 2021 in “Dermatology reports” Dupilumab can improve both atopic dermatitis and alopecia universalis.
March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
11 citations
,
January 2019 in “Acta Dermato Venereologica” Omalizumab may cause hair loss.
4 citations
,
October 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
December 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” The new vaccine platform led to a stronger immune response and better protection against the flu than the traditional vaccine.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet” 4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
33 citations
,
January 2019 in “Acta Dermato Venereologica” Dupilumab may help regrow hair in people with atopic dermatitis.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
7 citations
,
February 2010 in “British Journal of Dermatology” A woman with a rare autoimmune disorder had a blister on her eye and unique immune reaction, which was effectively treated with medication.